INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Portfolio Update as at 31 August 2016
|
Net Assets |
£217m |
|
Net Assets per share |
576p |
|
Share price |
498p |
|
Total value of unquoted investments |
£23m |
|
Total number of portfolio companies |
82 |
Top Ten Holdings
|
Company Name |
% NAV |
|
Biogen |
7.7 |
|
Celgene |
7.0 |
|
Regeneron |
6.3 |
|
Incyte |
5.2 |
|
Alexion |
4.7 |
|
Actelion |
4.6 |
|
Amgen |
3.8 |
|
Vertex |
3.6 |
|
Biomarin |
3.3 |
|
Exelixis |
3.1 |
|
|
----------- |
|
Total |
49.3 |
|
Geographical Allocation |
% NAV |
|
US & Canada |
78 |
|
Europe & UK |
22 |
|
|
----------- |
|
Total |
100 |
|
Quoted/Unquoted Allocation |
% NAV |
|
Quoted |
90 |
|
Unquoted |
10 |
|
|
----------- |
|
Total |
100 |
|
NAV % Market Cap |
% NAV |
|
Large Cap >USD10BN |
72 |
|
Small Cap <USD1BN |
23 |
|
Mid Cap =USD1-10BN |
5 |
|
|
----------- |
|
Total |
100 |
|
NAV % by Therapeutic Areas |
% NAV |
|
Oncology |
34 |
|
Orphan |
22 |
|
CNS |
10 |
|
Inflammation |
9 |
|
Ophthalmology |
8 |
|
Medtech |
1 |
|
Other |
16 |
|
|
----------- |
|
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
12 SEPTEMBER 2016